Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 20Gastrointestinal 9Head & Neck 5Tumor-Agnostic 4Genitourinary 2Dermatologic 2CNS 2Breast 2Sarcoma 1Plasma cell 1Lymphoid 1

Conditions

Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Neoplasms 1Melanoma 1Lung Neoplasms 1Leiomyosarcoma 1Kidney Neoplasms 1Histiocytoma, Malignant Fibrous 1Colonic Neoplasms 1Breast Neoplasms 1

Interventions

Paclitaxel 162Fulvestrant 157Trastuzumab 156pembrolizumab 145Letrozole 136Carboplatin 118pertuzumab 104Capecitabine 104Cyclophosphamide 102Specimen Handling 101Anastrozole 90palbociclib 86abemaciclib 82Magnetic Resonance Spectroscopy 80exemestane 76Docetaxel 76ribociclib 74Tamoxifen 74trastuzumab deruxtecan 67Radiotherapy 62Biopsy 58Surveys and Questionnaires 55Gemcitabine 53130-nm albumin-bound paclitaxel 53olaparib 52sacituzumab govitecan 51Blood Specimen Collection 50Standard of Care 49Taxes 48eribulin 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Erlotinib Hydrochloride × Breast × 1 year × Clear all
NCT00600496 2026-05-27

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

AstraZeneca

Phase 1 Completed
140 enrolled
BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms

NCT05827614 2026-01-23

POTENTIATE

Boundless Bio, Inc.

Phase 1 Active not recruiting
85 enrolled
BreastHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Leiomyosarcoma, Histiocytoma, Malignant Fibrous, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡